Research Presented at AUA 2024 Indicates Vasectomies Have Increased Since Dobbs Decision
Abstracts presented at the American Urological Association's Annual Meeting show increased vasectomy consults and procedures ...
Koelis Announces New Product Release at AUA 2024 to Offer Innovative AI-Enhanced MRI Fusion Biopsy Workflow
The Koelis Trinity ® system enables urologists to perform 3D targeted “fusion biopsy” in prostate cancer. Trinity integrates ...
Targeted Oncology1h
Williams on the Phase 3 SunRISe-2 Study of TAR-200/Cetrelimab in MIBC
Stephen Williams, MD, discusses the phase 3 SunRISe-2 study investigating TAR-200 plus cetrelimab in muscle-invasive bladder ...
The American Journal of Managed Care3d
AUA to Focus on Inclusive Care, Robotic Surgeries, and Future of Urology at 2024 Annual Meeting
The American Urological Association (AUA) 2024 Annual Meeting will highlight the latest innovations and future trends in ...
Medscape7d
AUA 2024: Awaiting New Data in the Treatment of Metastatic Prostate Cancer
Cite this: AUA 2024: Awaiting New Data in the Treatment of Metastatic Prostate Cancer - Medscape - Apr 26, 2024.
The American Journal of Managed Care3d
Latest Advances and Updates of Treatment in the Real World at AUA
The annual meeting of the American Urological Association (AUA) not only presents the newest therapies coming out but ...
Implantable Tibial Nerve Stimulation added as Treatment Option within AUA/SUFU 2024 OAB Guideline
Valencia Technologies is pleased to announce that implantable tibial nerve stimulation (ITNS) has been acknowledged as a ...
Krone4d
AUA to resume flights to Tehran from Thursday
Austrian Airlines (AUA) will soon resume its flights to Tehran, which were suspended following Iran's air attack on Israel.
Medscape7d
Conference MDAngle: AUA 2024 Metastatic Prostate Cancer
Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, ...
Business Insider1d
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Tyson, Urologic Oncologist at Mayo Clinic, at the 2024 American Urological Association (AUA) Annual Meeting, in San Antonio, TX. In addition, cretostimogene has shown durable responses over time with ...
Targeted Oncology19h
Experience With Cretostimogene Grenadenorepvec in NMIBC and Next Steps
Mark D. Tyson, II, MD, MPH, concludes his conversation on the BOND-003 trial by discussing the next steps for research on cretostimogene grenadenorepvec.